Company
Headquarters: Parsippany, NJ, United States
Employees: 697
CEO: Mr. David M. Stack
$1.13 Billion
USD as of Jan. 1, 2025
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Dec. 31, 2023 |
Revenue TTM | $675.0 M |
EBITDA | $171.2 M |
Gross Profit TTM | $490.3 M |
Profit Margin | 6.22% |
Operating Margin | 18.74% |
Quarterly Revenue Growth | 5.40% |
Pacira BioSciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: PCRX wb_incandescent
Stock: FSX: 82P wb_incandescent